Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Group 1 - Myriad Genetics reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of$ 0.05, and compared to a loss of $0.01 per share a year ago, indicating a 40% earnings surprise [1] - The company posted revenues of$ 195.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.03%, and down from $202.2 million year-over-year [2] - Myriad shares have declined approximately 43.8% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Group 2 - The earnings outlook for Myriad is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Myriad is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is$ 0.02 on revenues of $210.73 million, and for the current fiscal year, it is$ 0.09 on revenues of $845.32 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Myriad belongs, is currently in the top 31% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] - Wave Life Sciences, another company in the same industry, is expected to report a quarterly loss of$ 0.27 per share, reflecting a year-over-year change of -12.5%, with revenues anticipated to be $13.97 million, up 11.4% from the previous year [9][10]